|
|
|
|
Science Sparks @ ACTREC
|
 02 February 2026 |
Vol. No. 15 ; Issue No.720 |
|
|
Publications
|
|
1. Patil V, Shah P, Mahajan A, Sable N, Shukla A, Bornak G, Rane S, Gurav S, Laskar SG, Pantvaidya G, Janu A, Ankathi S, Sahu A, Bhattacharya K, Chakrabarty N, Agarwal A, Pai P, Nair D, Deshmukh A, Vaish R, Tuljapurkar V, Patil A, Bal M, Prabhash K, Noronha V, Menon N, Patil V, Chaturvedi P (2026). Decoding Osteoradionecrosis of the Jaw: Radiological Progression and a Novel CT-Based Grading System. Cancers 18(2):187.
2. Verma A, Hoysal DR, Deshpande A, Badwe R (2026).Letter to the Editor “Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor–positive, HER2-positive breast cancer”. The Breast.
Thesis
Darshankumar Mehta. 2026. Dissecting the role of Sfrp1 in epithelial cancer and cancer stem cells
( LIFE09201904006) (Guide: Dr. Sanjeev Waghmare)
|
|
|
|
|
Interesting Reads
|
|
Avsec Ž, Latysheva N, Cheng J, Novati G, Taylor KR, Ward T, Bycroft C, Nicolaisen L, Arvaniti E, Pan J, Thomas R, Dutordoir V, Perino M, De S, Karollus A, Gayoso A, Sargeant T, Mottram A, Wong LH, Drotár P, Kosiorek A, Senior A, Tanburn R, Applebaum T, Basu S, Hassabis D, Kohli P (2026). Advancing regulatory variant effect prediction with AlphaGenome. Nature.;649(8099):1206-1218.
|
|
|
Video of the Week
|
|
| Establishment of blood based Longitudinal Cohort: Indian Study of Healthy Ageing (ISHA) |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2018, FDA approved larotrectinib, the first drug that targets tumors with NTRK gene fusions.
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
